Файл: part16.pdf

Defined in Janmahasatian et al. Quantification of Lean​

Bodyweight. Clin Pharmacokinet. 2005 Oct​

1;44(10):1051-65. at http://dx.doi.org/10.2165/​

00003088-200544100-00004 and its role in​

SUVlbm(Janma) calculation is discussed in Tahari et al.​

Optimum Lean Body Formulation for Correction of​

Standardized Uptake Value in PET Imaging. Journal of​

Nuclear Medicine. 2014 Sep 1;55(9):1481-4. at http://​

jnm.snmjournals.org/content/55/9/1481.​

126406​ SUVlbm(James128)​

Standardized Uptake Value calculated using lean body​

mass by James method, using the originally published​

128multiplierformales.Thepatientsizecorrectionfactor​

formalesis1.10*weight-128)*(weight/height)^2,and​

for females is 1.07 * weight - 148 * (weight/height) ^2.​

Page 1326​

DICOM PS3.16 2020a - Content Mapping Resource​

Code Value​

Code Meaning​

Definition​

Notes​

126412​

SUV body surface area​

Method of calculating Standardized Uptake Value using​

calculation method​

body surface area. The patient size correction factor for​

males and females is weight^ 0.425 * height^0.725 *​

0.007184.​

Defined in Sugawara et al. Reevaluation of the​

Standardized Uptake Value for FDG: Variations with​

Body Weight and Methods for Correction.Radiology,​

1999 at http://radiology.rsna.org/content/213/2/521​

126413​ SUV ideal body weight​

Method of calculating Standardized Uptake Value using​

calculation method​

ideal body weight. The patient size correction factor for​

males is 48.0 + 1.06 * (height - 152) and for females is​

45.5 + 0.91 * (height - 152).​

Defined in Sugawara et al. Reevaluation of the​

Standardized Uptake Value for FDG: Variations with​

Body Weight and Methods for Correction.Radiology,​

1999 at http://radiology.rsna.org/content/213/2/521​

Janmahasatian method​

Uptake Value using lean body mass. The patient size​

correction factor for males is 9.27E3 * weight / (6.68E3​

+ 216 * weight / (height^2)) and for females is 9.27E3 *​

weight / (8.78E3 + 244 * weight / (height^2)).​

Defined in Janmahasatian et al. Quantification of Lean​

Bodyweight. Clin Pharmacokinet. 2005 Oct​

1;44(10):1051-65. at http://dx.doi.org/10.2165/​

00003088-200544100-00004 and its role in​

SUVlbm(Janma) calculation is discussed in Tahari et al.​

Optimum Lean Body Formulation for Correction of​

Standardized Uptake Value in PET Imaging. Journal of​

Nuclear Medicine. 2014 Sep 1;55(9):1481-4. at http://​

jnm.snmjournals.org/content/55/9/1481.​

method using 128 multiplier​

using lean body mass with the originally published 128​

multiplierformales.Thepatientsizecorrectionfactorfor​

males is 1.10 * weight - 128) * (weight/height) ^2, and​

for females is 1.07 * weight - 148 * (weight/height) ^2.​

thioflavin T.​

126501​

Florbetaben F^18^​

A beta-amyloid PET radiotracer.​

126502​

T807 F^18^​

A PHF-tau PET radiotracer.​

126503​

Flubatine F^18^​

A nicotinic α4β2 receptor (nAChR) PET radiotracer.​

126510​

Monoclonal Antibody (mAb)​

A Cu 64 Monoclonal Antibody (mAb) PET Radiotracer.​

^64^Cu​

126511​

Monoclonal Antibody (mAb)​

A Zr 89 Monoclonal Antibody (mAb) PET Radiotracer.​

^89^Zr​

126512​

Trastuzumab ^89^Zr​

A Zr 89

Trastuzumab PET Radiotracer.​

126513​

Cetuximab ^89^Zr​

A Zr 89

Cetuximab PET Radiotracer.​

126514​

J591 ^89^Zr​

A Zr 89

J591 PET Radiotracer.​

126515​

cU36 ^89^Zr​

A Zr 89 cU36 PET Radiotracer.​

126516​

Bevacizumab ^89^Zr​

A Zr 89

Bevacizumab PET Radiotracer.​

DICOM PS3.16 2020a - Content Mapping Resource​

Page 1327​

Code Value​

Code Meaning​

Definition​

Notes​

126517​

cG250-F(ab')(2) ^89^Zr​

A Zr 89 cG250-F(ab')(2) PET Radiotracer.​

126518​

R1507 ^89^Zr​

A Zr 89 R1507 PET Radiotracer.​

126519​

E4G10 ^89^Zr​

A Zr 89 E4G10 PET Radiotracer.​

126520​

Df-CD45 ^89^Zr​

A Zr 89 Df-CD45 PET Radiotracer.​

126600​

^44^Scandium​

^44^Scandium​

126601​

^51^Manganese​

^51^Manganese​

126602​

^70^Arsenic​

^70^Arsenic​

126603​

^90^Niobium​

^90^Niobium​

126604​

^191m^Iridium​

^191m^Iridium​

126605​

^43^Scandium​

^43^Scandium​

126606​

^152^Terbium​

^152^Terbium​

126607​

^52m^Manganese​

^52m^Manganese​

126700​

ATSM Cu^60^​

A Cu 60 ATSM PET radiotracer.​

126701​

ATSM Cu^61^​

A Cu 61 ATSM PET radiotracer.​

126702​

ATSM Cu^62^​

A Cu 62 ATSM PET radiotracer.​

126703​

Choline C^11^​

A C 11 Choline PET radiotracer.​

126704​

Fallypride C^11^​

A C 11 Fallypride PET radiotracer.​

126705​

Fallypride F^18^​

An F 18 Fallypride PET radiotracer.​

126706​

FLB 457 C^11^​

A C 11 FLB 457 PET radiotracer.​

126707​

Fluorotriopride F^18^​

An F 18 Fluorotriopride PET radiotracer.​

126708​

Fluoromisonidazole (FMISO)​

An F 18 Fluoromisonidazole PET radiotracer.​

F^18^​

126709​

Glutamine C^11^​

A C 11 Glutamine PET radiotracer.​

126710​

Glutamine C^14^​

A C 14 Glutamine PET radiotracer.​

126711​

Glutamine F^18^​

An F 18 Glutamine PET radiotracer.​

126712​

Flubatine F^18^​

An F 18 Flubatine PET radiotracer.​

Retired.​

Replacedwith(126503,DCM,​

"Flubatine F^18^").​

126713​

2FA F^18^​

An F 18 2FA PET radiotracer.​

126714​

Nifene F^18^​

An F 18 Nifene PET radiotracer.​

126715​

CLR1404 I^124^​

An I 124 cancer targeted phospholipid ether PET​

radiotracer.​

126716​

CLR1404 I^131^​

An I 131 cancer targeted phospholipid ether PET​

radiotracer.​

126717​

THK5351 F^18^​

A PET radiotracer used for tau brain imaging.​

Retired.​

Page 1328​

DICOM PS3.16 2020a - Content Mapping Resource​

Code Value​

Code Meaning​

Definition​

Notes​

126718​

Flurpiridaz F^18^​

APETradiotracerusedformyocardialperfusionimaging.​

SeeYuM,NekollaSG,SchwaigerM,RobinsonSP.The​

Next Generation of Cardiac Positron Emission​

Tomography Imaging Agents: Discovery of Flurpiridaz​

F-18 for Detection of Coronary Disease. Seminars in​

Nuclear Medicine. 2011 Jul;41(4):305-13.​

doi:10.1053/j.semnuclmed.2011.02.004​

SeeSNMMI.Flurpiridaz.http://interactive.snm.org/docs/​

PET_PROS/flurpiridaz_%2007_30_12_Final.pdf​

126719​

RO6924963 ^11^C​

A PET radiotracer used for tau brain imaging.​

See Wong DF, Comley R, Kuwabara H, Rosenberg PB,​

Resnick SM, Ostrowitzki S, et al. First in-human PET​

study of 3 novel tau radiopharmaceuticals:​

[11C]RO6924963, [11C]RO6931643, and​

[18F]RO6958948. J Nucl Med. 2018 May 4;​

doi:10.2967/jnumed.118.209916. http://​

jnm.snmjournals.org/content/early/2018/05/03/​

jnumed.118.209916​

126720​

RO6931643 ^11^C​

A PET radiotracer used for tau brain imaging.​

126721​

Obinituzimab ^89^Zr​

A Zr 89

Obinituzimab PET Radiotracer.​

126722​

Benralizumab ^89^Zr​

A Zr 89

Benralizumab PET Radiotracer.​

126723​

Ocaratuzumab ^89^Zr​

A Zr 89

Ocaratuzumab PET Radiotracer.​

126724​

Glembatumumabvedotin^89^Zr​A Zr 89

Glembatumumab vedotin PET Radiotracer.​

126725​

Pinatuzumab vedotin ^89^Zr​

A Zr 89

Pinatuzumab vedotin PET Radiotracer.​

126726​

Polatuzumab vedotin ^89^Zr​

A Zr 89

Polatuzumab vedotin PET Radiotracer.​

126727​

Blinatumomab ^89^Zr​

A Zr 89

Blinatumomab PET Radiotracer.​

126728​

Pegdinetanib ^89^Zr​

A Zr 89

Pegdinetanib PET Radiotracer.​

126729​

AGN-150998 ^89^Zr​

A Zr 89 AGN-150998 PET Radiotracer.​

126730​

MEDI-551 ^89^Zr​

A Zr 89 MEDI-551 PET Radiotracer.​

126731​

GA201 ^89^Zr​

A Zr 89 GA201 PET Radiotracer.​

126732​

Ecromeximab ^89^Zr​

A Zr 89 Ecromeximab PET Radiotracer.​

126733​

Roledumab ^89^Zr​

A Zr 89 Roledumab PET Radiotracer.​

126734​

XmAb5574 ^89^Zr​

A Zr 89 XmAb5574 PET Radiotracer.​

126735​

Brentuximab ^89^Zr​

A Zr 89

Brentuximab PET Radiotracer.​

126736​

Panitumumab ^89^Zr​

A Zr 89 Panitumumab PET Radiotracer.​

126737​

Rituximab ^89^Zr​

A Zr 89

Rituximab PET Radiotracer.​

126738​

Mogamulizumab ^89^Zr​

A Zr 89 Mogamulizumab PET Radiotracer.​

126739​

Ublituximab ^89^Zr​

A Zr 89

Ublituximab PET Radiotracer.​